Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Authors
Keywords
-
Journal
LANCET INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-08-27
DOI
10.1016/s1473-3099(22)00435-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019
- (2021) Laia Bruni et al. PREVENTIVE MEDICINE
- Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages
- (2020) Qi Chen et al. VACCINE
- Cervical cancer prevention in China: a key to cancer control
- (2019) Fanghui Zhao et al. LANCET
- Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial
- (2019) You-Lin Qiao et al. JNCI-Journal of the National Cancer Institute
- Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
- (2019) Mélanie Drolet et al. LANCET
- Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women
- (2019) YueMei Hu et al. Science China-Life Sciences
- Characterization of an Escherichia coli -derived human papillomavirus type 16 and 18 bivalent vaccine
- (2017) Ying Gu et al. VACCINE
- Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial
- (2016) Feng-cai Zhu et al. Cancer Medicine
- Long-Term Efficacy of a Hepatitis E Vaccine
- (2015) Jun Zhang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy
- (2013) Qinjian Zhao et al. Human Vaccines & Immunotherapeutics
- Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 population-based studies
- (2012) Fang-Hui Zhao et al. INTERNATIONAL JOURNAL OF CANCER
- Understanding and learning from the success of prophylactic human papillomavirus vaccines
- (2012) John T. Schiller et al. NATURE REVIEWS MICROBIOLOGY
- Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
- (2010) Feng-Cai Zhu et al. LANCET
- HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives
- (2009) Xavier Castellsagué et al. GYNECOLOGIC ONCOLOGY
- Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies
- (2009) Paul K.S. Chan et al. INTERNATIONAL JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started